Trodelvy (sacituzumab govitecan)

pCPA File Number: 21756
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease
Sponsor/Manufacturer:
Gilead Sciences Canada Inc.
CADTH Project Number:
PC0254
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable